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Mature T-Cell lymphoma (PTCL) is a heterogeneous group of
malignancies characterized by a poor outcome when treated
with antracycline-based chemotherapy regimens. High-dose
chemotherapy with autologous transplantation (auto-HCT)
has emerged as a commonly used strategy for patients in ﬁrst
remission or at the time of ﬁrst chemosensitive relapse.
However, data are limited and the role of autografting re-
mains undeﬁned. Here, we present a retrospective analysis of
67 patients with PTCL who underwent autoHCT at our center
between January 2000 and December 2011. Histological
subtypes included anaplastic large cell lymphoma (ALCL,
n¼27, 40.3%), peripheral T-cell lymphoma not other speciﬁed
(PTCL-NOS, n¼25, 37.3%), angioimmunoblastic T-cell lym-
phoma (AITL, n¼7, 10.4%), other (n¼8, 11.9%).
Median age at the time of auto-HCT was 52 years (22-75),
median time from diagnosis to HCT was 10 months (6-193)
and median follow up for surviving patients was 38 months
(6-136). Forty-one (61%) were male. At diagnosis, 52 (77%)
had stage III/IV, 39 (58%) had at least one extranodal site of
disease, 18 (27%) had intermediate-high or high-risk by in-
ternational prognostic index (IPI) and 16 (24%) had inter-
mediate-high or high-risk by PTCL prognostic index (PIT). At
transplantation, 32 (48%) had received 1 line of therapy and
35 (52%) had received 2 or more. Thirty-six patients (54%)
were in ﬁrst complete remission (CR1) and 62 (92%) had
shown sensitivity tomost recent therapy. BEAM (carmustine,
etoposide, cytarabine and melphalan) was used as condi-
tioning regimen in 52 patients (78%) and no patient received
a radiation based regimen.
Five-year overall survival (OS) was 65%. In univariate anal-
ysis, OS was associated with number of lines of therapy [>1
vs. 1, (Hazard ratio (HR)¼3.604; 95% CI: 1.335, 9.725;
p¼0.011)] and remission status [(CR1 vs. other (HR¼0.303,
95% CI: 0.124, 0.741; p¼0.009); (CR vs. other (HR¼ 0.223, 95%
CI: 0.096, 0.518; p¼0.0005)]. PFS was associated with age
[age >50 vs. 50 (HR¼2.308, 95% CI: 1.01, 5.26, p¼0.047)]
and remission status [CR1 vs. other (HR¼ 0.396, 95% CI:
0.185, 0.849, p¼0.017), CR vs. other (HR¼0.246, 95% CI: 0.115,
0.525, p<0.001)]. Only 4 patients died of causes other than
relapse.
In conclusion, patients with PTCL who underwent an auto-
HCT early in the course of the disease appear to beneﬁt the
most, achieving durable remissions. Disease relapse remains
the most common cause of failure. Maintenance strategieswith novel therapies remain a reasonable research question
to address in large prospective clinical trials.
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Background: Proteasome inhibitors (PI) impair the fanconi/
BRCApathwayofDNA repair and increaseDNA fragmentation
and apoptosis induced by alkylating agents in in vitro MM
cells. We hypothesized that combining carﬁlzomib, a second
generation PI, with melphalanwould result in more effective
anti myeloma activity. We herein performed a phase 1
study to identify the maximal tolerated dose (MTD) of car-
ﬁlzomib used in combinationwithmelphalan (200mg/m2) as
conditioning regimen prior to AHSCT for patients with
advanced MM.
Methods: Phase 1, multicentric, dose escalation trial with
traditional 3+3 design. Inclusion criteria required symp-
tomatic MM, relapse after at least one line of therapy (prior
AHSCT allowed), evaluable disease and at least minimal
response (MR) after the most recent salvage regimen. Sub-
jects were required to have at least 2 x 106 CD34+ cells/kg in
storage + 2 x 106 CD34+ cells/kg as “back up”. Treatment
consisted of two doses of carﬁlzomib administered IV over
30 minutes on days -3 and -2. The latter dose was adminis-
tered one hour prior to melphalan (Figure 1). Carﬁlzomib
dose consisted of 20(day-3)/27 (day -2) mg/m2 (cohort 0),
27/27 (cohort 1), 27/36 (cohort 2), 27/45 (cohort 3) and 27/56
mg/m2 (cohort 4). Dose limiting toxicities (DLT, non-hema-
tologic grade 4 and selected grade 3 toxicities) were evalu-
ated during the ﬁrst 30 days after AHSCT. Disease response
was assessed 100 days after AHSCT.
Results: Fifteen subjects were accrued in cohorts 0-4. At the
time of this report 14/15 subjects have completed the DLT
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cohort 4 (last cohort) is being treated. Median age was 54
(range 45-68). Median number of prior lines of therapy was 3
(range 2-6) and 7 subjects had previously received AHSCT.
Median CD34+ dose was 4.6 x 106/kg (range 2.21-9.34).
Median time for neutrophil engraftment was 11 days (range
8-15) and for platelet engraftment 18 days (range 11-24).
There were no non-hematologic grade 4 toxicities. The most
frequent grade 3 toxicity was infection in 8/14 subjects
consisting of 1 episode of pneumonia, 1 episode of bacter-
emia, 1 episode of urinary tract infection and 5 episodes of
febrile neutropenia. Other grade 3 toxicities were rash (n¼2),
hypertension (n¼1), hypophosphatemia (n¼1) and hypo-
calcemia (n¼1). Twelve subjects, from cohorts 0, 1, 2 and 3
have reached day +100 response assessment. Distribution of
subjects by category of response before and after AHSCT is
displayed in Figure 2.
Conclusion: Conditioning with carﬁlzomib and melphalan
prior to AHSCT is well tolerated in patients with relapsed
MM. Final results of this phase 1 study will be presented at
the meeting. TheMTD cohort (or cohort 4 if noMTD is found)
will be subsequently expanded to 28 subjects for better
determination of this regimen’s activity and toxicity.228
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AL amyloidosis is a plasma cell dyscrasia. It is a rare and fatal
progressive disease inwhich abnormal proteins misfold, form
ﬁbrils and deposit in one or more vital organs causing per-
manent tissue damage and failure. Timely diagnosis is are
crucial to improve the patient’s ability to tolerate more
aggressive and effective therapies, thus increasing their
chance of disease control and improved survival. New drugs
and treatment regimens are now available in addition to high
dose melphalan and stem cell transplantation (HDM/SCT).
However, disease complexity and factors involved in deter-
mining a patient’s best treatment options remain a challenge.
Utilizing a multidisciplinary team approach is critical in
enhancing communication between the referring physicians,
the clinical team members and the patient regarding the
extent of disease and the treatment plan. Clinical pathwaysand standard operating procedures are followed throughout
disease evaluation and treatment. Medical records and
pathology specimens are reviewed prior to the scheduled
appointments in the Multidisciplinary Amyloid Clinic to
establish the accurate pathologic subtyping of each amyloid
precursor protein and determine the evaluation plan. Each
new patient typically meets with an Amyloid Internist, He-
matologist, Cardiologist, Nephrologist and other specialists as
indicated based on the patient’s organ involvement and co-
morbidities. If a clinical trial or HDM/SCT is included among
the treatment options, a Research Nurse and/or Transplant
Nurse Practitioner meets with the patient and family to pro-
vide a program overview and protocol speciﬁcs. Weekly
meetings involving different professionals specialized in the
amyloid diseases, including Hematologists, Internists, Pa-
thologists, Cardiologists, Nephrologists, Pulmonologists, Psy-
chiatrists, Nutritionists, Clinical Research Staff, Insurance
Coordinators and Nurse Practitioners are essential to indi-
vidualized patient care. During weekly patient conferences,
team members provide input regarding clinical assessments
and test results obtained during the two-day comprehensive
disease evaluation. At thesemeetings, individual patient cases
are discussed in detail, treatment options reviewed and clin-
ical trial eligibility determined. Following the multidisci-
plinary review, the Amyloid Team discusses with each patient
the recommendations, the involved risks and beneﬁts of the
different treatment options and the next steps to be taken. In
addition, all results and recommendations are discussed with
the referring physician. A multidisciplinary team approach
allows for a timely, efﬁcient and effective method to deter-
mine and administer safe care to patients, especially in a rare
and complex multi-system disease such as AL amyloidosis.229
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In AML patients despite intensive chemotherapy and addi-
tional stem cell transplantation, residual leukemic stem cells
(LSC) may lead to relapse. Therefore, elimination of LSC by
targeted therapy may represent a promising therapeutic
approach. Recently CD96was identiﬁed asmarker antigen on
AML LSC (Hosen et al., PNAS 104: 11008, 2007). Here, stra-
tegies for engineering autologous stem cell grafts as well as
for in vivo targeting of residual AML stem cells by addressing
CD96 for magnetic cell sorting (MACS) or antibody depen-
dent cellular cytotoxicity (ADCC) are described. To evaluate
the efﬁcacy of purging LSC by MACS technology, stem cell
containing grafts were spiked with CD96 positive AML cells.
Using biotinylated CD96 antibody TH111 raised in our labo-
ratory in combination with anti-Biotin-microbeads (Milte-
nyi) up to a 1000-fold depletion of targeted cells was
achieved. Viability, cell count and the potential of HPC to
proliferate and differentiate were not affected by this pro-
cedure as shown by ﬂow cytometry and colony forming as-
says. Eradication of AML stems cells is also an issue after
allogeneic stem cell transplantation. To target CD96+ AML-
LSC by ADCC, chimeric antibodies containing wild type or
afﬁnity maturated variable regions in combination with an
optimized human IgG1 Fc were generated. As shown by ﬂow
cytometry, the antigen binding afﬁnity of the maturated
antibody was enhanced (EC50 0.6 mg/ml vs. 2 mg/ml).
Moreover, also NK cell mediated lytic properties against
CD96-positive target cells were elevated (EC50: 0.02 mg/ml
